When a young female panther in southern Florida was struck by a car and left severely injured, a team from the DePuy Synthes Vet business sprang into action, donating the proper medical devices to surgeons working to repair the animal’s broken leg.
In 2014, the world witnessed the largest and deadliest Ebola outbreak in history. By the end of the year, Ebola had infected nearly 20,000 people and killed close to 8,000 – including 375 health workers – across Guinea, Sierra Leone and Liberia, according to the World Health Organization. In response to the fast-growing global public health crisis, Johnson & Johnson announced it would quickly mobilize resources and scientific expertise to significantly expand production of a preventative vaccine program in development at its Janssen Pharmaceutical Companies.
For more than 80 years, Johnson & Johnson has had a strong commitment to caring for the health and well-being of families throughout Brazil. In 2014, Johnson & Johnson celebrated this long time presence in Brazil as the exclusive and official healthcare sponsor of the FIFA World Cup™.
The emergence of Ebola in West Africa has decimated the already fragile health care systems of Liberia, Sierra Leone and Guinea. Johnson & Johnson is participating in ongoing efforts by public health authorities and partners to strengthen the capacity of global health workers.
Mobile phones are all but ubiquitous in India, growing faster than any other regularly-consumed service, providing an opportunity to deliver vital health information directly to the women who need it most.
A great idea can come from anywhere and that is why we are collaborating with innovators and entrepreneurs everywhere. When we launched Johnson & Johnson Innovation – with teams in California, Boston, London and Asia Pacific – our aim was to contribute to the robust regional innovation ecosystems around the world and to support entrepreneurs and scientists with expertise in medical technologies, consumer healthcare technologies and therapeutics.
Oncology is one of five key areas of focus for Janssen Research & Development. We invite you to watch an interview with Peter Lebowitz, M.D., PhD, head of our oncology research and development about the strategy behind our cancer drug development as well as our approach to partnerships.
At the end of 2014, 73 products of the Johnson & Johnson Family of Companies have earned Earthwards® recognition, an honor that celebrates our most significant sustainability improvements.
Janssen Research & Development, LLC, launched a series of online videos during 2014 to address key mental health topics and treatments for disorders of the brain. Across the globe, approximately 450 million people suffer from a mental or neurological disorder.
A staggering one in five adults in the United States has some form of arthritis. DePuy Synthes Companies, a leader in joint reconstruction, commissioned an online Harris Poll survey in 2014 to gain deeper insights into patients’ views of living with joint pain.
A motorcycle traffic accident left Radha Kishan bedridden until an orthopaedic surgeon used the DePuy Synthes RIA System to help save Radha’s leg and get him back on his feet.
Johnson & Johnson provided Nurse.com with a grant to sponsor a continuing education campaign on Ebola risks and protocols to help nurses based in the United States better navigate the challenges of diagnosing, treating and protecting themselves. More than 40,000 nurses have taken the online class so far.
A new technology from the makers of LISTERINE® Mouthwash is helping consumers combat a common but serious oral health problem.
At Johnson & Johnson, our ability to design and manufacture better, more sustainable products is made possible by our employees’ innovative thinking, passion for sustainable solutions, and dedication to helping us reach our shared goal to improve the impacts across a product’s entire lifecycle – from formulation and manufacturing, to product use and end-of-life.
While tuberculosis (TB) is often considered a disease of the past, more people die from TB each year than from any other infectious disease, except for HIV/AIDS. Multidrug-resistant tuberculosis (MDR-TB) – TB infections resistant to at least two of the standard four-drug TB regimen – has emerged as a global health threat. In 2014, the Janssen Pharmaceutical Companies of Johnson & Johnson engaged with both new and longstanding partners in the global health community to address the MDR-TB epidemic.
In February 2014, the U.S. Food and Drug Administration approved Biosense Webster, Inc.’s THERMOCOOL SMARTTOUCH® Catheter, the first contact force therapy available for patients with drug-resistant, paroxsymal atrial fibrillation (Afib). Afib is the most common heart rhythm condition in the United States. More than three million Americans, the majority of whom are over age 65, live with Afib and as a result have a fivefold increased risk of stroke.
After Typhoon Haiyan wreaked havoc on the city of Tacloban in the Philippines in late 2013, Johnson & Johnson and partners built a playground to bring hope to the city’s children.
Our legacy of caring begins with caring for our employees. Data shows that a healthy workforce is a productive workforce and one that better contributes to society. For more than a century, Johnson & Johnson has been committed to a ‘culture of health’ for our global workforce.
When JOHNSON’S® Baby surveyed South African mothers in 2011, only 30 percent used shampoo to wash their babies’ hair. Usage was found to be particularly low among ethnic babies. Now, thanks to an innovative new product line that trend is changing.
Johnson & Johnson is committed to building the world’s best supply chain to safely and efficiently plan, source, make and deliver a high quality, reliable supply of all of the products in our global portfolio.
In 2014, we expanded our global innovation footprint when Johnson & Johnson Innovation announced the opening of the Asia Pacific Innovation Center. The Center will identify and develop promising early-stage opportunities across the Company’s three areas of focus: Pharmaceuticals, Medical Devices and Consumer healthcare products.
In 2010, Johnson & Johnson pledged to support the United Nations' Millennium Development Goals (MDG) 4, 5 and 6 with a comprehensive, five-year commitment to reach as many as 120 million women and children a year by 2015. Johnson & Johnson has been working side-by-side with implementing partners in 82 countries to reach more than 200 million women and children since 2010.
In 2014, Johnson & Johnson partnered with the International Center for Journalists (ICFJ) to sponsor a global maternal and child health reporting contest in BRIC (Brazil, Russia, India and China) countries to help improve access to information.
In 2014, Johnson & Johnson was honored to become the Official Healthcare Partner of the United Service Organizations (USO). For more than 70 years, the USO’s mission has been to lift the spirits of America’s troops and military families through a range of programs that are delivered at more than 160 locations worldwide.
More than 3.2 million children are living with HIV worldwide and without treatment half of those children will die before age 2. Johnson & Johnson, driven by our purpose of caring, remains committed to the prevention, detection, education and treatment of HIV/AIDS.
Johnson & Johnson continues to find new ways to produce the products our customers need while using fewer raw materials and reducing waste. We accomplish this by finding innovative ways to put waste to use instead of using more raw materials, an approach referred to as “closing the loop.”
After the success of the CLEAN & CLEAR® SEE THE REAL ME™ campaign in the U.S., the brand adapted the initiative for teens in other markets.
The World Health Organization estimates 600 million adults were obese in 2014, and the epidemic continues to grow. Since 2000, Ethicon has taken the lead to stem the tide by driving a deeper understanding of the science of obesity through metabolic research and clinical trials.
Our Safety & Care Commitment means that our products are supported by science, recommended by healthcare professionals, and trusted by people around the world. You have our commitment that every beauty and baby care product from the Johnson & Johnson Family of Consumer Companies is safe and effective when used as directed.
Johnson & Johnson set new industry standard in 2014 by establishing a collaboration with Yale University School of Medicine’s Open Data Access (YODA) that made Johnson & Johnson the first company to share clinical trial data for pharmaceutical products through an independent third-party. Under the agreement, the YODA Project serves as an independent authority to decide what clinical trials data from Johnson & Johnson’s pharmaceutical companies will be shared with which researchers. In 2015, Johnson & Johnson extended the agreement to cover clinical trials by its medical devices companies.
TYLENOL® – a brand with a rich history in family – put a modern spin on Norman Rockwell’s iconic painting, Freedom From Want, to help illustrate how today’s families come together to celebrate what matters most.
For many older adults, one of their greatest joys in life is seeing their grandchildren flourish and grow. But what happens when those grandchildren are located hundreds—or even thousands—of miles away?
Overcoming obstacles is something Sebastien Sasseville relishes. He’s conquered Everest. Completed six Ironman® triathlons. Finished the mythical Sahara race in Egypt. And he’s lived with Type 1 diabetes through it all.
Read about a few of the products that earned our highest level of sustainability - the Earthwards® recognition.